Recent Updates
Recently added Catalysts
TVGN Positive Sentiment

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

Key Takeaway: Tevogen Inc. announced it has regained compliance with Nasdaq's listing requirements. The company met the $50 million minimum market value of listed securities requirement. This follows a previous notice confirming compliance with the minimum market value of publicly held shares. All related Nasdaq compliance matters are now resolved.
Price reaction · baseline $6.62 (2026-09-30 close) · hit after-hours · clean, no other TVGN news in the window
day 0 close
+1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Regained compliance with Nasdaq listing requirements.
  • Minimum market value of listed securities requirement met.
  • Compliance matters are now closed.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~0 mo
High dilution risk
Lead asset
Cytotoxic T Lymphocytes
Phase 1 · Covid19

Full Press Release Details

WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”)on September 29, 2026, confirming that the Company had regained compliance with the $50 million minimum market value of listed securities requirement under Nasdaq Listing Rule 5450(B)(2)(A) for continued listing on The Nasdaq Global Market.
As previously announced, on September 9, 2026, the Company had received written notice from Nasdaq confirming that it had regained compliance with the minimum market value of publicly held shares requirement under Nasdaq Listing Rules 5450(B)(2)(C) and 5450(B)(3)(C).
With both requirements satisfied, the related Nasdaq compliance matters are now closed.

About Tevogen

Tevogen is a healthcare enterprise focused on improving the affordability and accessibility of life-saving medicines. The Company brings together three complementary efforts: Tevogen Bio, its biotechnology initiative; Tevogen.AI, its artificial intelligence and technology initiative; and Tevogen Healthcare Services, its emerging healthcare services initiative.
Together, these efforts are designed to create a more integrated healthcare model in which science, technology, and operational efficiency work together to reduce the cost of medication and expand patient access.

Frequently Asked Questions

What compliance did Tevogen regain?

Tevogen regained compliance with Nasdaq's listing requirements.

What is the minimum market value for Nasdaq?

The minimum market value is $50 million.

When did Tevogen receive the compliance notice?

Tevogen received the notice on September 29, 2026.

Are there any outstanding compliance matters?

No, all related Nasdaq compliance matters are now closed.

Last updated: Sep 30, 2026